相关临床试验
114
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1967
进行中（未招募）
1
0.9%
已完成
99
86.8%
招募中
4
3.5%
终止
3
2.6%
撤回
7
6.1%
暂无批准数据
- Researchers at the University of Dundee discovered cabamiquine, a novel drug-like antimalarial molecule deliverable in a single dose. - An early-stage clinical trial showed cabamiquine combined with pyronaridine is effective with a favourable safety profile in adults and adolescents. - The single-dose regimen has potential to simplify dosing for malaria treatment and prevention in areas with challenging healthcare delivery. - Medicines for Malaria Venture intends to advance the cabamiquine-pyronaridine combination into larger trials and pediatric studies.
- Researchers at the University of Dundee used cryo-electron microscopy and AI to reveal previously invisible molecular details of how protein degrader drugs work, showing how they position disease-causing proteins for destruction. - The study demonstrates how protein degraders capture disease-causing proteins and position them for effective tagging by ubiquitin molecules, which marks them for cellular destruction. - This breakthrough provides unprecedented molecular-level understanding that could accelerate development of new targeted protein degradation drugs for diseases previously considered 'undruggable'. - More than 50 protein degrader drugs are currently in clinical trials, representing a revolutionary approach to treating diseases where conventional drugs have failed.
- The UK government has awarded £650,000 to launch the Scotland CardioMetabolic Impact Study (SCoMIS), a groundbreaking research initiative targeting 3,000-5,000 participants from Scotland's most deprived communities to evaluate real-world impact of GLP-1 weight-loss medicines. - The study represents a collaboration between Novo Nordisk, IQVIA, and Scottish universities to assess incretin-based treatments' effectiveness in primary care settings, with full launch planned for 2026 and potential funding extending to 2029-2030. - More than one in three adults in Scotland's most deprived areas live with obesity, making this research critical for addressing health inequalities and potentially guiding NHS commissioning decisions for weight-loss medications. - The study will examine four key areas: delivery effectiveness in NHS care, weight loss outcomes in disadvantaged populations, impact on healthcare costs, and broader societal benefits including work productivity and reduced sick leave.
- The UK's MHRA has launched three AI-powered projects totaling over £2 million to predict harmful drug interactions before they reach patients and streamline regulatory processes. - The flagship study will use AI to analyze anonymized NHS data to identify dangerous drug combinations, focusing initially on cardiovascular medicines, with lab validation using human-based models. - Drug interaction side effects currently cause approximately one in six hospital admissions in England and cost the NHS more than £2 billion annually. - The initiative includes AI-assisted regulatory tools and synthetic patient data pilots to strengthen evidence in rare disease trials while maintaining human oversight of all final decisions.
- Scientists from six leading European research institutions published a perspective in Molecular Cell proposing a European Alliance to accelerate development of proximity-induced drug modalities like PROTACs and molecular glue degraders. - These revolutionary therapeutics can remove entire disease-causing proteins by reprogramming cellular machinery, offering new possibilities for previously "undruggable" targets that conventional inhibitors cannot address. - The proposed alliance aims to pool expertise across European hubs in Frankfurt, Barcelona, Dundee, Lausanne, and Vienna to facilitate technology benchmarking, integrate computational approaches, and develop in vivo models. - The initiative builds on Germany's PROXIDRUGS Cluster4Future, which has secured €5 million annual funding since 2021 and seeks to expand internationally through academic-industry collaboration.
- A collaborative team from University of Dundee, GSK, and University of Exeter has received £17.9 million from Wellcome to develop new antifungal treatments over five years. - The project targets Cryptococcus neoformans, which causes meningitis and kills approximately 180,000 HIV patients annually, and Candida auris, a climate change-linked pathogen with over 40% fatality rates. - The initiative aims to generate two pre-clinical drug candidates for cryptococcal meningitis with broad-spectrum potential, addressing critical gaps in antifungal drug development. - Fungal infections cause around 2.5 million deaths worldwide annually, yet the drug development pipeline remains severely limited with increasing resistance and poor diagnostics.
